These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17974962)

  • 1. Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis.
    Decock J; Long JR; Laxton RC; Shu XO; Hodgkinson C; Hendrickx W; Pearce EG; Gao YT; Pereira AC; Paridaens R; Zheng W; Ye S
    Cancer Res; 2007 Nov; 67(21):10214-21. PubMed ID: 17974962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression.
    Hughes S; Agbaje O; Bowen RL; Holliday DL; Shaw JA; Duffy S; Jones JL
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6673-80. PubMed ID: 18006768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphisms of the CYP19A1 gene and breast cancer survival.
    Long JR; Kataoka N; Shu XO; Wen W; Gao YT; Cai Q; Zheng W
    Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2115-22. PubMed ID: 17119036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea.
    Han W; Kang D; Lee JE; Park IA; Choi JY; Lee KM; Bae JY; Kim S; Shin ES; Lee JE; Shin HJ; Kim SW; Kim SW; Noh DY
    Clin Cancer Res; 2005 Jul; 11(13):4775-8. PubMed ID: 16000574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression.
    Lei H; Hemminki K; Altieri A; Johansson R; Enquist K; Hallmans G; Lenner P; Försti A
    Breast Cancer Res Treat; 2007 May; 103(1):61-9. PubMed ID: 17033924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of polymorphisms and haplotypes in the human growth hormone 1 (GH1) gene with breast cancer.
    Wagner K; Hemminki K; Israelsson E; Grzybowska E; Klaes R; Chen B; Butkiewicz D; Pamula J; Pekala W; Försti A
    Endocr Relat Cancer; 2005 Dec; 12(4):917-28. PubMed ID: 16322331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of interleukin-10 gene variation with breast cancer prognosis.
    Gerger A; Renner W; Langsenlehner T; Hofmann G; Knechtel G; Szkandera J; Samonigg H; Krippl P; Langsenlehner U
    Breast Cancer Res Treat; 2010 Feb; 119(3):701-5. PubMed ID: 19437115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of MMP8 gene variation with an increased risk of malignant melanoma.
    Dębniak T; Jakubowska A; Serrano-Fernández P; Kurzawski G; Cybulski C; Chauhan SR; Laxton RC; Maleszka R; Lubinski J; Ye S
    Melanoma Res; 2011 Oct; 21(5):464-8. PubMed ID: 21642878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes.
    Riaz M; Berns EM; Sieuwerts AM; Ruigrok-Ritstier K; de Weerd V; Groenewoud A; Uitterlinden AG; Look MP; Klijn JG; Sleijfer S; Foekens JA; Martens JW
    Breast Cancer Res Treat; 2012 Jun; 133(3):843-51. PubMed ID: 21748294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of matrix metalloproteinase-9 protein polymorphisms with lymph node metastasis but not invasion of gastric cancer.
    Tang Y; Zhu J; Chen L; Chen L; Zhang S; Lin J
    Clin Cancer Res; 2008 May; 14(9):2870-7. PubMed ID: 18451255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in telomere-associated genes, breast cancer susceptibility and prognosis.
    Varadi V; Brendle A; Brandt A; Johansson R; Enquist K; Henriksson R; Svenson U; Tavelin B; Roos G; Hemminki K; Lenner P; Försti A
    Eur J Cancer; 2009 Nov; 45(17):3008-16. PubMed ID: 19766477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival.
    Zhang X; Shu XO; Cai Q; Ruan Z; Gao YT; Zheng W
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6037-42. PubMed ID: 17062678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
    Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients.
    Bonafé M; Ceccarelli C; Farabegoli F; Santini D; Taffurelli M; Barbi C; Marzi E; Trapassi C; Storci G; Olivieri F; Franceschi C
    Clin Cancer Res; 2003 Oct; 9(13):4860-4. PubMed ID: 14581358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinase 8 (MMP8) gene polymorphisms in chronic periodontitis.
    Izakovicova Holla L; Hrdlickova B; Vokurka J; Fassmann A
    Arch Oral Biol; 2012 Feb; 57(2):188-96. PubMed ID: 21920499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An association between the matrix metalloproteinase 1 promoter gene polymorphism and lymphnode metastasis in breast cancer.
    Przybylowska K; Zielinska J; Zadrozny M; Krawczyk T; Kulig A; Wozniak P; Rykala J; Kolacinska A; Morawiec Z; Drzewoski J; Blasiak J
    J Exp Clin Cancer Res; 2004 Mar; 23(1):121-5. PubMed ID: 15149160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker.
    Brendle A; Lei H; Brandt A; Johansson R; Enquist K; Henriksson R; Hemminki K; Lenner P; Försti A
    Carcinogenesis; 2008 Jul; 29(7):1394-9. PubMed ID: 18550570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel functional polymorphism in the transforming growth factor-beta2 gene promoter and tumor progression in breast cancer.
    Beisner J; Buck MB; Fritz P; Dippon J; Schwab M; Brauch H; Zugmaier G; Pfizenmaier K; Knabbe C
    Cancer Res; 2006 Aug; 66(15):7554-61. PubMed ID: 16885354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
    Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
    Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer.
    Papadopoulou E; Simopoulos K; Tripsianis G; Tentes I; Anagnostopoulos K; Sivridis E; Galazios G; Kortsaris A
    Neoplasma; 2007; 54(5):365-73. PubMed ID: 17918664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.